Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

Biopharmaceutical company Angitia Biopharmaceuticals has begun a Phase II clinical trial of AGA2118, a bispecific antibody designed for treating osteoporosis. The first patient has been dosed in the ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

Bright Minds Biosciences' BMB-101 shows promise in treating drug-resistant epilepsy. Read why DRUG stock is a strong ...

A first healthy adults group has been dosed in an early clinical trial of an oral and myelin-protective treatment for all types of MS.

Recce Pharmaceuticals is nearing completion in its Phase II clinical trial for acute bacterial skin and skin structure ...

Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing its proprietary ReSOLVE™ platform to discover and develop differentiated sma ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of ...

The initial trio of patients with glioblastoma have begun treatment with ropidoxuridine in a phase 2 clinical trial, ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

Shuttle Pharmaceuticals Holdings announced it has finalized agreements with all six of the planned site enrollment locations to administer the Phase 2 clinical trial of Ropidoxuri ...

The Phase 2a PSP Clinical Trial was a 24-week, randomized, double-blind, placebo-controlled, prospective exploratory clinical trial conducted in 78 patients with PSP at 5 centers in Korea.